An accompanying editorial said that based on the risk of gastrointestinal (GI) events found in this retrospective study, sodium polystyrene sulfonate should not be used to reduce serum potassium levels.
A systematic review and network meta-analysis focused on alosetron, eluxadoline, ramosetron, and rifaximin in adult patients who had irritable bowel syndrome (IBS) with diarrhea or mixed stool.
A retrospective trial showed no increase in new corticosteroid therapy or disease-related hospitalization or surgery among patients who discontinued 5-aminosalycilate (5-ASA) therapy when initiating an anti-tumor necrosis factor (anti-TNF) agent.
In a meta-analysis of 22 studies in patients with nonalcoholic fatty liver disease (NAFLD), weight loss interventions were associated with improvements in alanine aminotransferase level, liver steatosis, histologic NAFLD activity score, and
Infliximab may have been used inappropriately in Crohn's disease and underused in ulcerative colitis, according to the authors of an analysis of hospitalizations, intestinal resections, and drug costs related to inflammatory bowel disease (IBD).
Based on the results, study authors suggested expanding colorectal cancer (CRC) screening to patients 45 years of age, but an accompanying editorial expressed concern that the risks could outweigh the benefits in the general population.
Researchers at three Australian hospitals assigned patients with active ulcerative colitis to receive fecal microbiota transplant infusions from three to seven unrelated donors or placebo infusions.
Patients with irritable bowel syndrome (IBS) who had been randomized to receive remote cognitive behavioral therapy (CBT) had lower symptom severity scores than those who had received usual care, according to follow-up data from a British trial.
About 84% of participants randomly assigned to receive rifabutin in addition to amoxicillin and omeprazole achieved Helicobacter pylori eradication, compared to 58% of those who received amoxicillin and omeprazole alone.
Age, presence of diabetes, and platelet count were significant predictors of hepatic events up to 12 years from the time of nonalcoholic fatty liver disease (NAFLD) diagnosis, a retrospective study found.